Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

7C7F

Crystal structures of AKR1C3 binary complex with NADP+

Summary for 7C7F
Entry DOI10.2210/pdb7c7f/pdb
DescriptorAldo-keto reductase family 1 member C3, NADP NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE, 1,2-ETHANEDIOL, ... (5 entities in total)
Functional Keywordscancer, oxidoreductase
Biological sourceHomo sapiens (Human)
Total number of polymer chains2
Total formula weight75953.89
Authors
Irie, K.,Toyooka, N.,Endo, S. (deposition date: 2020-05-25, release date: 2020-09-23, Last modification date: 2023-11-29)
Primary citationEndo, S.,Oguri, H.,Segawa, J.,Kawai, M.,Hu, D.,Xia, S.,Okada, T.,Irie, K.,Fujii, S.,Gouda, H.,Iguchi, K.,Matsukawa, T.,Fujimoto, N.,Nakayama, T.,Toyooka, N.,Matsunaga, T.,Ikari, A.
Development of Novel AKR1C3 Inhibitors as New Potential Treatment for Castration-Resistant Prostate Cancer.
J.Med.Chem., 63:10396-10411, 2020
Cited by
PubMed Abstract: Aldo-keto reductase (AKR) 1C3 catalyzes the synthesis of active androgens that promote the progression of prostate cancer. AKR1C3 also contributes to androgen-independent cell proliferation and survival through the metabolism of prostaglandins and reactive aldehydes. Because of its elevation in castration-resistant prostate cancer (CRPC) tissues, AKR1C3 is a promising therapeutic target for CRPC. In this study, we found a novel potent AKR1C3 inhibitor, -(4-fluorophenyl)-8-hydroxy-2-imino-2-chromene-3-carboxamide (), and synthesized its derivatives with IC values of 25-56 nM and >220-fold selectivity over other AKRs (1C1, 1C2, and 1C4). The structural factors for the inhibitory potency were elucidated by crystallographic study of AKR1C3 complexes with and . The inhibitors suppressed proliferation of prostate cancer 22Rv1 and PC3 cells through both androgen-dependent and androgen-independent mechanisms. Additionally, and prevented prostate tumor growth in a xenograft mouse model. Furthermore, the inhibitors significantly augmented apoptotic cell death induced by anti-CRPC drugs (abiraterone or enzalutamide).
PubMed: 32847363
DOI: 10.1021/acs.jmedchem.0c00939
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.7 Å)
Structure validation

237735

数据于2025-06-18公开中

PDB statisticsPDBj update infoContact PDBjnumon